Vasomotor Symptoms Clinical Trial
— GLAMOfficial title:
Effectiveness of Integral Yoga on Objective and Subjective Menopausal Hot Flashes
Verified date | August 2018 |
Source | Wake Forest University Health Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this research study is to compare yoga and health and wellness classes for helping perimenopausal or newly postmenopausal women who are experiencing hot flashes. The investigators want to learn about the effects of yoga and health and wellness classes on symptoms and other quality of life issues. The results of this study may provide important knowledge to women and clinicians who counsel women with menopausal hot flashes.
Status | Completed |
Enrollment | 54 |
Est. completion date | May 2011 |
Est. primary completion date | May 2011 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 45 Years to 58 Years |
Eligibility |
Inclusion Criteria: - At least 2 months since last menses - Age 45-58 years - Moderate to severe vasomotor symptoms for at least 4 weeks (at least 4/day on average) - Self-reported general good health - Adequate English to understand informed consent form, questionnaires, and converse with study staff - Agree not to use pharmaceutical agents for treating hot flashes during the study Exclusion Criteria: - Hormone therapy use within 12 weeks prior to study screening, including systemic estrogen, progestin or androgen therapy - Selective estrogen receptor modulator (Evista® and Novaldex®) or aromatase inhibitor use within 6 months - Cancer at any time - Untreated thyroid disease - Initiation of herbal or nutritional supplements for hot flashes within the past 4 weeks - Significant psychiatric disorder, including regular use of antidepressants or anxiolytics - Regular use of clonidine or Bellergal® within the past 12 weeks - Any past use of yoga for hot flashes - Yoga or Acupuncture for any reason within the past 3 months |
Country | Name | City | State |
---|---|---|---|
United States | Wake Forest University Health Sciences | Winston-Salem | North Carolina |
Lead Sponsor | Collaborator |
---|---|
Wake Forest University | National Center for Complementary and Integrative Health (NCCIH) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Subjective Hot Flashes | Subjective hot flashes measured by daily diaries | Weekly | |
Secondary | Objective hot flashes | Objective hot flashes measured by skin conductance. | 3 days | |
Secondary | Hot flash interference | This measure assesses the impact of hot flashes on daily activities and quality of life. | 1 week |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04090957 -
Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women
|
Phase 3 | |
Completed |
NCT01052454 -
Mindfulness-Based Stress Reduction for Hot Flashes
|
Phase 0 | |
Completed |
NCT00535288 -
Dose-Finding Safety and Efficacy Trial of Org 50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (177001/P06472/MK-8265-013)
|
Phase 3 | |
Recruiting |
NCT00906308 -
A Study of MF101 in Postmenopausal Women
|
Phase 3 | |
Completed |
NCT01452373 -
Dehydroepiandrosterone (DHEA) + Acolbifene Against Vasomotor Symptoms (Hot Flushes) in Postmenopausal Women
|
Phase 3 | |
Completed |
NCT00560833 -
Dose-Finding Safety and Efficacy Trial of Org50081 (Esmirtazapine) in the Treatment of Vasomotor Symptoms (46101/P06459/MK-8265-012)
|
Phase 3 | |
Completed |
NCT05033886 -
A Study of Fezolinetant to Treat Hot Flashes in Women Going Through Menopause
|
Phase 3 | |
Completed |
NCT05083884 -
A Survey About Hot Flashes in Women Going Through the Menopause
|
||
Completed |
NCT01178892 -
MsFLASH-02: Interventions for Relief of Menopausal Symptoms: A 3-by-2 Factorial Design Examining Yoga, Exercise, and Omega-3 Supplementation
|
N/A | |
Completed |
NCT00397176 -
Study Evaluating Safety, Tolerability, and PK of DVS SR in Healthy Japanese Women
|
Phase 1 | |
Recruiting |
NCT06122181 -
Study of HS-10384 in Participants of Chinese Postmenopausal Women
|
Phase 1 | |
Not yet recruiting |
NCT06393673 -
A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women
|
Phase 2 | |
Withdrawn |
NCT02202707 -
Vasomotor Symptoms and Cardiovascular Control
|
N/A | |
Completed |
NCT00356447 -
Safety/Efficacy Study of Drospirenone/Estradiol to Treat Postmenopausal Chinese Women With Vasomotor Symptoms.
|
Phase 3 | |
Completed |
NCT05312567 -
FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms
|
Phase 2 | |
Terminated |
NCT01353963 -
Desvenlafaxine Succinate (Pristiq): Postmarketing Surveillance Study Among Filipino Patients
|
Phase 4 | |
Completed |
NCT00446199 -
Low-dose Hormone Therapy for Relief of Vasomotor Symptoms
|
Phase 3 | |
Completed |
NCT05850338 -
Determination of the Effects of Autogenic Relaxation Exercise and Cold Pillow Application on Vasomotor Symptom Control and Quality of Life in Postmenopausal Women
|
N/A | |
Completed |
NCT02803268 -
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of MT-8554 in Female Subjects Experiencing Vasomotor Symptoms
|
Phase 1 | |
Completed |
NCT00683800 -
Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women
|
Phase 3 |